The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Japan’s Eisai and US biotech Biogen today revealed that the Ministry of Health and Prevention in the United Arab Emirates (UAE) has approved Leqembi (lecanemab) for the treatment of Alzheimer’s disease (AD). 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
An agreement between the University of Hong Kong and the Shanghai Institute of Infectious Disease and Biosecurity (SIIDB) will pave the way for the establishment of a new research institute dedicated to tackling infectious diseases. 3 November 2023
US trade group the Biotechnology Innovation Organization (BIO) has joined more than 1,300 companies and associations in signing a letter sent to congressional leaders yesterday to urge extension of longstanding tax incentives for research and development. 3 November 2023
Lexeo Therapeutics has announced the final pricing of its initial public offering of 9,090,910 shares of common stock at a price to the public of $11.00 per share. 3 November 2023
Boston, USA-based non-profit the Institute for Clinical and Economic Review (ICER) has published a report on barriers to fair access in the US insurance industry. 3 November 2023
The American business of Israeli drugmaker Teva Pharmaceutical has announced new Huntington’s disease (HD) data to be presented at the ongoing Huntington Study Group annual meeting. 3 November 2023
Independent French drugmaker Pierre Fabre has expanded a global partnership for Ebvallo (tabelecleucel) with US biotech Atara Biotherapeutics. 3 November 2023
AstraZeneca has presented positive results from the real-world ZORA trial, at the annual congress of the American Society of Nephrology (ASN). 3 November 2023
San Diego, USA-based biotech AnaptysBio’s ground breaking Phase III trial results for imsidolimab, a novel inhibitor, bring renewed hope to patients battling generalized pustular psoriasis (GPP). 3 November 2023
San Diego, USA-based precision medicine firm Kura Oncology’s shares rose 4% to $8.31 yesterday, after it announced a research collaboration with Mirati Therapeutics. 3 November 2023
Eli Lilly has reported strong revenues for the third quarter, with blockbuster diabetes med Mounjaro (tirzepatide) doing much of the heavy lifting. 2 November 2023
US mRNA specialist Moderna today reported financial results for the third quarter of 2023 that disappointed, sending its shares down 8.9% to $69.23 in early trading. 2 November 2023
Regeneron Pharmaceuticals today announced financial results for the third quarter of 2023, showing that total revenues for the quarter came in at $3,363 million, rise of 15%, and beating consensus forecasts by 5%. 2 November 2023
US ophthalmic drug developer Aldeyra Therapeutics saw its shares leap 48.5% to $2.54 yesterday after it announced the signing of a deal with pharma major AbbVie 2 November 2023
The Crohn's disease (CD) treatment arena is set for a notable transformation, with novel therapies expected to drive significant market growth. 2 November 2023
The European Medicines Agency (EMA) has validated the submission for Braftovi (encorafenib) with Mektovi (binimetinib), submitted by privately-held French drugmaker Pierre Fabre, for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC). 2 November 2023
Indian contract development and manufacturing organization (CDMO) Aragen is to build a new biologics manufacturing facility in Bangalore. 2 November 2023